Shanghai Ruijin Hospital, Comprehensive Breast Health Center, Shanghai, 200025, China.
Cancer Immunol Immunother. 2014 Apr;63(4):395-406. doi: 10.1007/s00262-014-1519-x. Epub 2014 Feb 11.
The programmed death-1 (PD-1) molecule is mainly expressed on functionally "exhausted" CD8(+) T cells, dampening the host antitumor immune response. We evaluated the ratio between effective and regulatory T cells (Tregs) and PD-1 expression as a prognostic factor for operable breast cancer patients. A series of 218 newly diagnosed invasive breast cancer patients who had undergone primary surgery at Ruijin Hospital were identified. The influence of CD8(+) cytotoxic T lymphocytes, FOXP3(+) (Treg cell marker), and PD-1(+) immune cell counts on prognosis was analyzed utilizing immunohistochemistry. Both PD-1(+) immune cells and FOXP3(+) Tregs counts were significantly associated with unfavorable prognostic factors. In bivariate, but not multivariate analysis, high tumor infiltrating PD-1(+) cell counts correlated with significantly shorter patient survival. Our results suggest a prognostic value of the PD-1(+) immune cell population in such breast cancer patients. Targeting the PD-1 pathway may be a feasible approach to treating patients with breast cancer.
程序性死亡受体-1(PD-1)分子主要表达在功能上“耗竭”的 CD8(+)T 细胞上,从而抑制宿主抗肿瘤免疫反应。我们评估了有效 T 细胞(Teffs)和调节性 T 细胞(Tregs)与 PD-1 表达的比值作为可手术乳腺癌患者的预后因素。本研究共纳入了 218 例在瑞金医院接受初次手术的新诊断浸润性乳腺癌患者。采用免疫组化法分析 CD8(+)细胞毒性 T 淋巴细胞、FOXP3(+)(Treg 细胞标志物)和 PD-1(+)免疫细胞计数对预后的影响。PD-1(+)免疫细胞和 FOXP3(+)Tregs 计数均与不良预后因素显著相关。在单变量分析中,但不是多变量分析中,高肿瘤浸润 PD-1(+)细胞计数与患者生存时间显著缩短相关。我们的结果表明,PD-1(+)免疫细胞群体在这类乳腺癌患者中有预后价值。靶向 PD-1 通路可能是治疗乳腺癌患者的可行方法。